Real‐World Efficacy of Postoperative Adjuvant Nivolumab in High‐Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population

Adjuvant nivolumab demonstrated clinical benefit in Asian patients with high-risk urothelial carcinoma in a real-world setting.

Authors

Takahiro Inaba
Hiroaki Iwamoto (ORCID: https://orcid.org/0000-0003-3599-2217)
Shuhei Aoyama (ORCID: https://orcid.org/0000-0003-0540-7590)
Takahiro Nohara (ORCID: https://orcid.org/0000-0001-9792-2068)
Taiki Kamijima (ORCID: https://orcid.org/0009-0003-2553-0497)
Shohei Kawaguchi (ORCID: https://orcid.org/0000-0001-6847-9861)
Renato Naito
Atsushi Mizokami (ORCID: https://orcid.org/0000-0002-5643-2182)
Hiroshi Yaegashi (ORCID: https://orcid.org/0000-0003-3188-8834)
Kazuyoshi Shigehara (ORCID: https://orcid.org/0000-0002-2118-9135)
Ryunosuke Nakagawa (ORCID: https://orcid.org/0000-0002-2503-8908)
Kouji Izumi (ORCID: https://orcid.org/0000-0002-8480-9100)
Ren Toriumi (ORCID: https://orcid.org/0000-0002-6951-8524)
Suguru Kadomoto (ORCID: https://orcid.org/0000-0003-4136-8998)
Tomoyuki Makino (ORCID: https://orcid.org/0000-0003-2554-7048)
Hiroshi Kano (ORCID: https://orcid.org/0000-0002-3543-1236)